Atorvastatin Calcium
Product Images NDC 68071-2342

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Atorvastatin Calcium (NDC 68071-2342). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals,inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pdp (68071 2342 3)

This is a product label for NuCare Pharmaceuticals' Atorvastatin Calcium 40mg tablets, with lot number 000000 and National Drug Code 68071-2342-03. Each film-coated tablet contains Atorvastatin Calcium equivalent to 40mg Atorvastatin. The round white tablet is debossed with "40" on one side. The product should be stored at a controlled temperature of 68-77°F and kept out of reach of children. The label includes a warning to call a doctor for medical advice about side effects and the contact information for the FDA.*

FDA Label Image

Chemical Structure (Atorvastatin Calcium Tablets 1)

FDA Label Image

Figure 1 (Atorvastatin Calcium Tablets 2)

The text shows a graph of cumulative incidence over a period of 35 years. Additionally, it includes the hazard ratio (0.64) with its confidence interval (0.50-0.83) and p-value (0.0005). However, there is not enough information to know what is being measured or compared.*

FDA Label Image

Figure 2 (Atorvastatin Calcium Tablets 3)

The text describes a statistical analysis with a graph showing the cumulative hazard over time for an endpoint. The hazard decreases over time with HR of 0.63 and significant p-value. The x-axis represents time in years, up to 5 years, and the y-axis shows the percentage of cumulative hazard.*

FDA Label Image

Figure 3 (Atorvastatin Calcium Tablets 4)

This is a summary of subjects and their corresponding percentages experiencing cardiovascular events during a study involving Atorvastatin at two different doses, 10mg and 80mg. The study found a significant improvement in cardiovascular outcomes (HR 0.78, P=0.0002) for patients taking Atorvastatin 80mg as compared to Atorvastatin 10mg. The chart displays the time to the first major cardiovascular endpoint over a four year period.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.